Transcript identification in the BRCA1 candidate region by Abel, Kenneth J. et al.
Breast Cancer Research and Treatment 33:115-124, 1995. 
© 1995 Kluwer Academic Publishers. Printed in the Netherlands'. 
Molecular Genetics in Breast C a n c e r -  minisymposium 
Transcript identification in the BRCA1 candidate region 
Barbara L. Weber, MD 1'*, Kenneth J. Abel, PhD 1, Fergus J. Couch, PhD t, Sofia Merajver, MD, PhD 1, 
Lucio Castilla, MS 2, Lawrence C. Brody, PhD 3, Francis S. Collins, MD, PhD 3 
Departments of  Internal Medicine 1, and Biology 2, University of Michigan, Ann Arbor, MI; and National 
Center for Human Genome Research 3, Bethesda, MD 
Key words: BRCA1, breast/ovarian cancer susceptibility gene, cDNA, exon amplification, molecular 
cloning, tumor suppressor gene 
Summary 
Chromosome 17q12-21 is known to contain a gene (or genes) which confers susceptibility to early-onset 
breast cancer and ovarian cancer (BRCA1). Identification and isolation of BRCA1 will likely provide the 
basis for increased understanding of the pathogenesis of breast and ovarian cancer, the development of 
targeted diagnostic and therapeutic approaches, and a means of screening women at risk of being BRCA1 
mutation carriers. Genetic and physical maps of the BRCA1 candidate region have been largely completed 
and efforts are being directed at identification of candidate genes from within this region. We have begun 
the task of identifying transcripts from this region employing three complementary strategies, These 
include: 1) direct cDNA screening with cosmids derived from the BRCA1 region; 2) exon amplification; 
and 3) magnetic bead capture. Transcripts identified using these approaches are being characterized for: 
1) tissue expression pattern; 2) the presence of genomic rearrangement in DNA derived from affected 
members of families believed to show linkage between breast cancer and genetic markers in the BRCA1 
candidate interval; 3) altered size and/or expression pattern in RNA prepared from such individuals; and 
4) homology to known genes or functional motifs. Germline mutations in affected individuals from these 
families will serve as presumptive evidence of BRCA1 identity. 
Introduction 
Family history has long been known to be a 
major contributor to breast cancer risk, but has 
frequently been assumed to be the result of com- 
plex interactions between multiple factors. This 
may in fact be true for a significant percentage of 
breast cancer cases. However, a landmark study, 
published in 1990, demonstrated the existence of 
a breast cancer susceptibility gene on the long 
arm of human chromosome 17 [1]. Using genetic 
linkage analysis, Hall et al. convincingly demon- 
strated that alterations in this putative gene, now 
termed BRCA1, were inherited in an autosomal 
dominant manner and conferred a high risk of de- 
veloping early onset breast cancer in a subset of 
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families. A subsequent report confirmed these 
findings and extended the observation to include 
susceptibility to ovarian cancer [2]. More re- 
cent studies indicate that about half of families 
with apparent autosomal dominant transmission of 
breast cancer susceptibility show linkage to 
genetic markers in this region. For families with 
both breast and ovarian cancer, the linked fraction 
may be greater than 90% [3]. Although estimates 
of the percentage of all breast cancer cases which 
occur as a direct result of germline mutations in 
BRCA1 vary from five to twenty percent [4-7], 
what is certain is that the estimates must be a 
function of age. Thus, although less than 5% of 
all breast cancers in elderly women are likely to 
result from BRCA1 germline mutations, this frac- 
tion may be much greater for women diagnosed 
with breast cancer under the age of 45 [3]. 
The findings of Hall et al. opened the door to 
the use of positional cloning aimed at isolation of 
BRCA1. The cloning of BRCA1 will have vast 
significance for several reasons. The most im- 
mediate effect will likely be the development of 
predictive testing for breast cancer. At present, 
genetic counseling based on linkage analysis is 
possible for only very few families. Once this 
gene has been isolated and common mutations 
characterized, identification of carriers will likely 
be able to be performed on individuals, without 
the requirement for study of entire large families. 
Perhaps of even greater significance, isolation and 
cloning of BRCA1 should ultimately lead to a 
more detailed understanding of the biology of 
breast cancer. It is hoped that the insights de- 
rived from the study of BRCAI will give us new 
and more effective means to diagnose, treat, and 
ultimately prevent breast cancer. 
BRCA1 is a putative tumor suppressor gene 
Loss of heterozygosity (LOH) at a specific 
chromosomal location in tumors is widely inter- 
preted as a marker for the absence of a functional 
tumor suppressor gene. Non-random deletions, as 
detected by LOH at specific chromosomal re- 
gions, have been identified in a number of com- 
mon human cancers, including carcinoma of the 
breast, supporting this hypothesis. In the case of 
inherited mutations in putative tumor suppressor 
genes, it is generally accepted that the germline 
mutation constitutes the "first hit" required for 
malignant transformation. In this setting, the 
subsequent somatic loss of the non-mutant allele 
represents the "second hit" [8]. Thus germline 
mutations in tumor suppressor genes create a 
highly susceptible group of individuals for whom 
only one somatic event is required to produce 
inactivation of tumor suppressor activity at a 
given locus. Recent evidence [9,10] demonstra- 
ting loss of non-mutant alleles flanking BRCA1 in 
breast tumors from affected members of linked 
families strongly supports the theory that BRCA1 
is a tumor suppressor gene. 
Identification of LOH at specific chromosomal 
locations has proven to be a useful tool not only 
for locating tumor suppressor genes, but for 
narrowing the candidate interval which must con- 
tain the sought-after gene. The location of the 
DCC gene, thought to play an important role in 
the development of colorectal cancer, was identi- 
fied solely on the basis of LOH studies [11]. The 
candidate interval for the retinoblastoma gene was 
also significantly narrowed by defining small 
interstitial deletions in familial tumor specimens 
[12]. We have similarly used LOH analysis to 
decrease the size of the BRCA1 candidate region 
as defined by genetic linkage analysis. 
Positional cloning 
Functional cloning of a disease-related gene 
requires information on the gene product. Un- 
fortunately, in the case of BRCA1, all that is 
known about the gene is the approximate chromo- 
somal location and the phenotype of carrier 
females. As such, we have used a strategy 
initially referred to as reverse genetics, now 
termed positional cloning [13], in our attempts to 
isolate BRCA1. Positional cloning has been suc- 
cessfully employed to clone a number of genes 
mediating important genetic diseases, including 
cystic fibrosis [14], neurofibromatosis [15], 
myotonic dystrophy, and Huntington disease [l 6]. 
It was also useful in identifying the familial 
adenomatous polyposis (APC) gene on chromo- 
some 5q21 [17]. 
The positional cloning approach, as applied to 
the BRCA1 effort, is as outlined: 1) Families 
with apparent autosomal dominant transmission of 
breast cancer were studied with a large number of 
polymorphic genetic markers representing the 
entire human genome. A 20 cM region of chrom- 
osome 17q21 was identified as the original can- 
didate interval [1]. 2) Additional families were 
studied to confirm the finding and demonstrate 
susceptibility to ovarian cancer in the same 
families [2]. 3) The candidate interval was 
saturated with polymorphic markers, and the order 
of these markers along the chromosome was de- 
termined by the complementary methods of radi- 
ation hybrid mapping, fluorescence in situ 
hybridization mapping, and genetic mapping [18- 
20]. 4) The candidate interval was narrowed 
from 20 cM to less than 4 cM by genotyping 
families believed to show linkage between breast/ 
ovarian cancer and genetic markers on chrom- 
osome 17q with additional polymorphic markers 
in the region looking for recombination events 
[10,21,22]. 5) A physical map was constructed 
using yeast artificial chromosomes, pulsed-field 
gel electrophoresis (PFGE), and cosmid clones 
from a flow-sorted human chromosome 17 cosmid 
library provided by the Los Alamos National 
Laboratory. 6) Genes within the bounded region 
are now being identified by exon amplification 
[23], direct screening of cDNA libraries with 
cosmid clones from the region, and magnetic bead 
capture [24,25]. These transcripts are being 
examined for tissue distribution, mutations in 
affected individuals, and alterations between 
normal and malignant breast tissue. Demonstra- 
tion of germline mutations in affected individuals 
from linked families will be accepted as presump- 
tive evidence of gene identity. 
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Candidate genes 
The ultimate goal of positional cloning is the 
identification of a disease-related gene. As noted 
above, several efficient methods are now available 
to isolate genes contained within genomic DNA 
fragments. However, a logical first step is to 
examine all known genes within the candidate 
region. The original BRCA1 candidate interval 
contained several previously-cloned genes which 
could be candidates for BRCA1. Any gene with 
biological properties suggesting that it could play 
a role in the development of breast and ovarian 
cancer needs to be excluded by recombination 
events or examined for the presence of germline 
mutations in affected members of linked families 
before it can be excluded as a potential candidate. 
Genes encoding nm-23 H1 and H2, (NME1 and 
NME2), retinoic acid receptor ~-subunit (RARA), 
topoisomerase II o~-subunit (TOP2A), gastrin 
(GAS), 17-hydroxysteroid dehydrogenase (EDH- 
17B), a small nuclear ribonucleoprotein (RNU2), 
and pancreatic polypeptide (PPY) were at one 
time all within the BRCA1 candidate region. All 
but GAS, TOP2A, EDH-17B, RNU2, and PPY 
have been excluded by genetic analysis of linked 
families. Of these, EDH-17B seems the most 
plausible candidate. This enzyme, which is ex- 
pressed in many normal and neoplastic tissues, 
catalyzes the interconversion of estrone and 
estradiol. The latter is a hormone known to play 
a role in the growth regulation of breast cancer 
cell lines in vitro. However, to date, no germline 
mutations of the EDH-17B gene have been des- 
cribed in affected members of families in which 
the disease is thought to be linked to BRCA1 
[22]. As no convincing candidate genes have 
been identified, we have turned to strategies 
which allow identification of novel genes within 
the candidate interval. 
Transcript identification 
The final step in positional cloning of any 
disease-related gene involves the isolation and 
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characterization of transcribed sequences from the 
genomic region that defines the candidate interval. 
Until recently, methods of finding transcripts 
tended to be laborious and cumbersome when the 
candidate interval spanned several hundred 
thousand to a few million base pairs. With the 
advent of several new transcript identification 
techniques, the effort required for isolation of 
transcripts from large genomic regions has been 
considerably lessened. In the past, isolation of 
coding regions from large genomic fragments 
were limited to strategies designed to identify 
sequences which are highly conserved among spe- 
cies (and therefore likely to represent coding 
regions) and the identification of sequence mo- 
tifs present at the 5' end of many genes (CpG 
islands). Optimization of hybridization conditions 
and attempts to exploit splicing signals within 
transcripts have allowed us to apply several more 
efficient methods to the isolation of BRCA1. 
Direct eDNA screening 
Direct screening of cDNA libraries is conceptual- 
ly the most straight forward of the three methods 
presented here. In brief, direct screening involves 
radioactive labeling of large regions of cloned 
genomic DNA (40-200 kb) and the use of this 
material to probe cDNA libraries. The result 
should be the isolation of transcripts from the 
region of interest. Although appealing in its 
simplicity, the method has enough drawbacks that 
it best serves to complement the other methods 
described here rather than supplant them. 
It is estimated transcribed genes make up no 
more than 10% of the human genome. The re- 
mainder of the human genome consists of non- 
transcribed DNA between and within genes, and 
many families of repetitive elements. This 
noncoding DNA is not useful for screening cDNA 
libraries because it is either not transcribed, or 
transcribed but not unique to a given region of the 
genome (i.e. transcribed repetitive elements). 
Early positional cloning methods stripped the 
genomic DNA of these "extraneous" sequences by 
first isolating non-repetitive DNA from genomic 
clones; however, this method is cumbersome and 
time-consuming for large chromosomal regions. 
If the candidate interval is defined by genetic 
recombination as is the case for BRCA1, it is 
likely to be a megabase or larger. For genomic 
regions this large, it is most efficient to directly 
label large clones such as cosmids (approximately 
50 kb) or yeast artificial chromosomes (YACs, 
100-1000 kb) and eliminate the time consuming 
step of subcloning single copy sequences. The 
tradeoff is that complex probes are more difficult 
to use for cDNA library screens. YACs have the 
additional complication that they are difficult to 
purify from the contaminating yeast genomic 
DNA. In the case of the BRCA1 region, we are 
using cosmids which have been individually 
labeled and pooled in groups of two to six 
cosmids each. To eliminate hybridization to 
transcribed repetitive sequences represented in a 
cDNA library, the probes are preannealed to a 
vast excess of unlabeled human genomic DNA. 
The preannealing conditions are chosen such that 
any highly repetitive probe sequences are bound 
to the cold competitor DNA and therefore are not 
available to hybridize to the filter-bound cDNAs. 
On average, the genome contains an expressed 
sequence about every 50 kb. If human breast 
tissue expresses half of all genes, we would 
expect to find an expressed sequence with each 
cosmid probe used; in actuality we have been 
isolating approximately half that number. This 
may represent the actual distribution of genes in 
this region of chromosome 17 or a lack of sensi- 
tivity of the direct screening method. Genes may 
be missed for the following reasons: 1) Direct 
screening is biased towards the isolation of genes 
with large exons. In most cases the 3' terminal 
exon is the largest single exon in a gene. We 
have chosen to screen oligo dT-primed cDNA 
libraries to maximize the number of clones con- 
taining a complete 3' terminal exon. 2) The low 
"specific" activity of the probes with respect to 
coding sequences leads to a low signal to noise 
ratio when compared to traditional probes. In 
many cases positive phage plaques are barely 
above the background; therefore, cDNAs hybrid- 
izing at or just below this threshold are also 
missed. 
Falsely positive clones are primarily repetitive 
transcribed sequences. These sequences might 
not be sufficiently blocked by the preannealing 
procedure and will be present in many cDNA lib- 
raries. For this reason, every candidate clone is 
hybridized to a somatic cell hybrid panel to con- 
firm that it maps to the BRCA1 region of chrom- 
osome 17 with a hybridization pattern suggestive 
of single copy DNA. 
Exon amplification 
Exon amplification, also called exon trapping, is 
a powerful technique for isolating gene sequences 
from genomic clones. This technique relies on 
the normal processing of most primary RNA tran- 
scripts, whereby noncontiguous sequences des- 
tined to make up the mature messenger RNA 
(exons) are accurately spliced together and the 
intervening sequences (introns) are excised. The 
exons are flanked by specific sequences which 
serve as signposts for the cellular splicing 
machinery, identifying the precise sites where 
cutting and joining of the exons occurs. Exon 
amplification permits the selective recovery of 
sequences present in cloned genomic DNA which 
are flanked by functional splice sites, yielding 
subclones from genomic DNA which are highly 
enriched for gene sequences. 
We have successfully used exon amplification 
[23] to isolate coding sequences from cosmids 
derived from the BRCA1 candidate region. Brief- 
ly (see Figure 1), cosmid DNAs are digested and 
ligated into a plasmid splicing vector. The 
original vector, pSPL1, contained only a single 
cloning site; recent modifications to this vector 
include multiple cloning sites, permitting greater 
flexibility in the types of restriction fragments 
which can be used. The fragments are inserted 
into an intron of the HIV tat gene which is 
flanked by functional donor and acceptor splice 
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sites. The resulting constructs are transfected into 
COS-7 cells where in vivo processing pairs exons 
present in the genomic fragment with the tat 
donor and acceptor splice sites in the vector. The 
tat intron sequences are excised and the exon is 
now present in the mature mRNA. After a brief 
period in culture, cytoplasmic RNA is isolated 
from the cells and used as a template to generate 
cDNA using reverse transcriptase. The first 
strand cDNAs are made double stranded and amp- 
lified by PCR using nested, vector-specific 
primers, then cloned into plasmids and propagated 
in bacteria. Within one week, large numbers of 
candidate exon clones can be generated by this 
method. Starting with approximately 120 cosmid 
DNAs organized into pools of 6-10 each, we have 
generated more than 1300 exon clones derived 
from the BRCA1 region. 
In order to eliminate redundancy, we have 
arrayed the exon clones on nylon filters, and 
probed the filters by hybridization with PCR- 
amplified inserts from individual clones. We 
have observed an average redundancy of 5 to 
10-fold, although the range has varied consider- 
ably above and below this average. Non-redun- 
dant, representative clones which are shown to be 
single copy in hybridization tests with genomic 
DNA, and which map back to the correct chrom- 
osomal region, are then used as hybridization 
probes to screen cDNA libraries for larger 
corresponding clones. Approximately one-third of 
tested clones have yielded cognate cDNAs in our 
screening of libraries derived from normal breast. 
It is expected that a much higher fraction of 
clones would identify cDNAs in a comprehensive 
survey of a variety of tissues, as it has been 
reported that greater than 90% of clones generated 
by this method are likely to represent "true" exons 
[26]. 
The technique of exon amplification has a 
number of inherent advantages. First, large 
numbers of candidate gene sequences can be 
generated from regionally localized genomic DNA 
clones in a relatively short period of time. 
Second, coding sequences can be obtained irres- 
pective of the sites or levels of expression of the 
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Figure 1. Outline of exon amplification method for isolating coding sequences. 
corresponding gene, theoretically permitting 
isolation of genes expressed at very low levels 
within a highly restricted set of cell types. Third, 
more than 90% of clones have been free of repeti- 
tive sequences and are therefore useful as hybridi- 
zation probes without additional competitor DNA. 
Fourth, the exon clones are typically short enough 
(average <200 base pairs) to permit rapid se- 
quence analysis of the cloned inserts, enabling 
high volume sequencing of many clones simultan- 
eously. In an effort to predict potential functions 
of the corresponding genes, the sequences deter- 
mined for each representative clone can be used 
to screen databases of nucleic acid and protein 
sequences for homologies with known genes. 
Finally, the ability to pool cosmids means that 
large genomic regions can rapidly be surveyed for 
genes by this technique. 
There are also a number of limitations unique 
to this method. First, several types of artifactual 
products can arise from aberrant splicing events 
including pairing of only the vector splice sites, 
cloning of noncoding sequences which are flanked 
by "cryptic" splice sites within the insert and/or 
vector, or cloning of sequences which derive en- 
tirely from the HIV tat  intron. In the original 
system using pSPL1, these cloning artifacts 
represented nearly half of the clones generated. 
However recent modifications to the vector [25] 
have greatly reduced the frequency of vector-only 
and cryptic splicing artifacts, and efficient liga- 
tion of genomic fragments and vector can nearly 
eliminate the background of tat intronic clones. 
Second, while only a few percent of our clones 
were found to contain highly repetitive sequences, 
it appears that highly repetitive Alu sequences 
may continue to be cloned as a result of splicing 
events. We and others [27] have observed that 
specific sequences within Alu repeats can act as 
donor and acceptor splice junctions. Third, be- 
cause of the short average length of the cloned 
exons, some of the clones may be difficult to use 
as hybridization probes. Finally, while the re- 
quirement for two flanking splice sites provides 
greater reliability for amplifying internal exons, 
this technique is not designed to isolate the 5'- or 
3'-most exons of genes, and thus is not expected 
to efficiently amplify sequences from genes with 
less than three exons. However, a version of this 
technique has been reported recently which targets 
the 3' exons of genes [28]. 
Magnetic bead capture of cDNA 
Magnetic bead capture is based on solution 
hybridization of cDNAs to immobilized region- 
specific genomic DNA fragments. Originally 
genomic DNA was immobilized on nylon filters 
[24]; this technique has subsequently been modi- 
fied to take advantage of magnetic beads as the 
genomic fragment support system [25]. Briefly 
(see Figure 2), cosmid DNA from the BRCA1 
candidate interval is digested with a frequent- 
cutter restriction enzyme and ligated to linkers 
which contain the appropriate restriction site and 
unique sequence complementary to the biotin- 
ylated PCR primers being used for subsequent 
amplification, cDNAs from appropriate libraries 
(breast and ovary in this case) are also PCR- 
amplified using vector primers and hybridized at 
high stringency to the biotinylated genomic frag- 
ments. The biotinylated genomic-cDNA com- 
plexes are captured with streptavidin-coated para- 
magnetic beads (Dynal), and washed to remove 
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unbound and non-specific cDNAs. The captured 
cDNAs, enriched for sequences from the chrom- 
osomal region the cosmids are derived from, are 
eluted by boiling and PCR-amplified with vector 
primers. Following purification and size selec- 
tion of fragments greater than 200 bp in length, 
cDNAs are subcloned as a region-specific sub- 
library. Larger cDNAs are analyzed to determine 
if they map back to the original cloned genomic 
DNA or contain repetitive and/or vector se- 
quences. Each clone which maps back to the 
region can then be used to: 1) determine the size 
of the full length cDNA by Northern blot analy- 
sis; 2) isolate the full length transcript from 
cDNA libraries; and 3) generate cDNA sequence 
from the gene for homology searches in genome 
databases. 
We have successfully utilized this technique 
to isolate several hundred cDNA fragments from 
the BRCA1 candidate region. In this case, small 
pools of 7-10 overlapping cosmids served as the 
genomic DNA template. Of those tested, 72% of 
cDNAs have been shown to map back to the orig- 
inal genomic clones, 12% contained only repeti- 
tive sequences, 6% were cosmid vector fragments, 
and 10% did not map back, suggesting that these 
clones originated in other genomic regions and 
were captured non-specifically. As both genomic 
and cDNA clones are PCR-amplified, a singular 
advantage of this technique is that only small 
quantities of starting materials are required. An 
additional advantage of this approach is the speed 
with which large DNA segments can be screened 
for the presence of transcribed genes. In general, 
the technique is highly efficient, and may be 
applied to several sources of cDNA simultaneous- 
ly or in parallel reactions. When random-primed 
cDNA libraries are used as starting material, 
cDNA fragments obtained are randomly distri- 
buted over each mRNA, aiding in rapid genera- 
tion of full length cDNA clones. Furthermore, 
the method may normalize transcript levels, with 
enrichment of rare messages. 
Several limitations are associated with this 
method. First, the small size of the captured 
subclones necessitates re-screening of cDNA 
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Figure 2. Outline of magnetic bead capture of specific cDNA fragments. 
libraries to obtain full length cDNA. Secondly, 
genomic clones which contain expressed repeat 
sequences can result in capture of a large number 
of cDNAs containing these repeats. Once identi- 
fied, these repetitive sequences can be used to 
pre-screen the sublibrary of captured clones or 
can be added as a blocking agent to any future 
capture experiments in the region. Thirdly, 
because the technique is based on hybridization, 
pseudogenes and multigene family members may 
be enriched. These clones can be excluded at an 
early stage by the more stringent hybridization 
conditions associated with mapping the cDNA 
back to the original parent genomic clones. 
Transcript characterization 
BRCA1 candidate genes identified by any of 
these methods are being used to screen RNA blots 
from a variety of normal tissues, including breast 
and ovary. The results of  these experiments 
provide information on the expected size of the 
full-length transcript. Primary tumors and tumor 
cell lines derived from these tissues are also being 
screened as BRCA1 may be differentially ex- 
pressed in normal and malignant tissue. It is also 
possible that transcripts from breast tumors and/or 
obligate mutation carriers may be altered with 
respect to size. The proof of  correctness of a 
candidate gene will be the identification of 
specific DNA abnormalities in germline DNA of 
affected individuals from linked families. Ac- 
cordingly, genomic DNA from families in which 
breast cancer is linked to genetic markers on 
chromosome 17q is being surveyed for mutations 
in candidate genes using Southern blotting and 
more sensitive methods such as chemical mis- 
match cleavage [29], single-strand conformation 
polymorphism screening (SSCP) [30] or PCR 
sequencing. Somatic mutations in tumors will 
provide supporting evidence, but as has been 
recently demonstrated for the MCC gene [31] in 
familial polyposis and the prohibitin gene in 
breast cancer [32], these may not always indicate 
the gene responsible for inherited disease. 
Conclusion 
BRCA1 is a highly penetrant breast/ovarian 
cancer susceptibility gene on the long arm of 
human chromosome 17. We and others are at- 
tempting to isolate BRCA1 using a positional 
cloning approach. Following publication of the 
location of  this gene as defined by genetic linkage 
analysis [1], we have narrowed the candidate 
interval by further genetic analysis of  affected 
families and studies of allelic loss in tumors from 
these families, generated and ordered new poly- 
morphic markers within and flanking the candi- 
date interval and developed a physical map of the 
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region. We now have turned our efforts to tran- 
script identification within the candidate interval. 
We are currently using three complementary ap- 
proaches dependent on region-specific cosmids, 
including direct screening of cDNA libraries, 
exon amplification, and magnetic bead capture. 
It is hoped that this intensive approach will lead 
to the isolation of BRCA1 in the near future, the 
identification of  which is likely to provide impor- 
tant insights into the pathophysiology of  breast 
cancer. 
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